'Click' D1 receptor agonists with a 5-HT1A receptor pharmacophore producing D2 receptor activity

被引:38
作者
Zhang, Jing [2 ]
Zhang, Hai [1 ]
Cai, Wenxian [1 ]
Yu, Leiping [1 ]
Zhen, Xuechu [1 ]
Zhang, Ao [2 ]
机构
[1] Chinese Acad Sci, Shanghai Inst Mat Med, Neuropharmacol Lab, Shanghai 201203, Peoples R China
[2] Chinese Acad Sci, Shanghai Inst Mat Med, SOMCL, Shanghai 201203, Peoples R China
基金
美国国家科学基金会;
关键词
Arylbenzazepine; Arylpiperazine; Click reaction; Dopamine receptor; Serotonin 5-HT1A receptor; PARKINSONS-DISEASE; SEROTONIN; LIGANDS; COMPLICATIONS; DOPAMINE-D-2; THERAPEUTICS; DERIVATIVES; THERAPY;
D O I
10.1016/j.bmc.2009.06.019
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A series of new 1-aryl-3-benzazepine derivatives containing an arylpiperazinyl function as the N3 substituent were synthesized by combining a D-1 receptor agonistic pharmacophore and a 5-HT1A receptor pharmacophore through Click reaction. Interestingly, these compounds generally do not have good binding affinity at the D-1 receptor, but most compounds are potent at both D-2 and 5-HT1A receptors. Compound 8h, containing 1-m-tolyl-benzazepine scaffold and 2-methoxyphenylpiperazine core, displayed good affinity at all tested receptors, with K-i values of 144, 80, and 133 nM, for the D-1, D-2, and 5-HT1A receptors, respectively. Compound 13 with the triazole moiety formed differently from that in 8h showed the highest affinity at the D-2 receptor with K-i value of 19 nM. This compound also showed moderate affinity at the 5-HT1A (K-i, 105 nM), and D-1 (K-i, 551 nM) receptors. Functional assays indicated that both compounds 13 and 8h are antagonists at D-1 and D-2 receptors, whereas full agonistic activity at the 5-HT1A receptor was observed. In agreement with the binding affinity, compound 13 is a high efficacy D-2 antagonist and 5-HT1A agonist. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:4873 / 4880
页数:8
相关论文
共 50 条
[41]   Indoloxypropanolamine analogues as 5-HT1A receptor antagonists [J].
Krushinski, Joseph H., Jr. ;
Schaus, John M. ;
Thompson, Dennis C. ;
Calligaro, David O. ;
Nelson, David L. ;
Luecke, Susan H. ;
Wainscott, David B. ;
Wong, David T. .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (20) :5600-5604
[42]   Curated Database and Preliminary AutoML QSAR Model for 5-HT1A Receptor [J].
Czub, Natalia ;
Paclawski, Adam ;
Szlek, Jakub ;
Mendyk, Aleksander .
PHARMACEUTICS, 2021, 13 (10)
[43]   Anxiolytic activities of Matcha tea powder, extracts, and fractions in mice: Contribution of dopamine D1 receptor- and serotonin 5-HT1A receptor-mediated mechanisms [J].
Kurauchi, Yuki ;
Devkota, Hari Prasad ;
Hori, Kengo ;
Nishihara, Yuiko ;
Hisatsune, Akinori ;
Seki, Takahiro ;
Katsuki, Hiroshi .
JOURNAL OF FUNCTIONAL FOODS, 2019, 59 :301-308
[44]   5-HT1A and 5-HT1B receptor agonists and aggression:: A pharmacological challenge of the serotonin deficiency hypothesis [J].
de Boer, SF ;
Koolhaas, JM .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2005, 526 (1-3) :125-139
[45]   Imipramine increases the 5-HT1A receptor-mediated inhibition of hippocampal neurons without changing the 5-HT1A receptor binding [J].
Bijak, M ;
Tokarski, K ;
Czyrak, A ;
Mackowiak, M ;
Wedzony, K .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1996, 305 (1-3) :79-85
[46]   Synthesis and biological evaluation of 1,3-dioxolane-based 5-HT1A receptor agonists for CNS disorders and neuropathic pain [J].
Franchini, Silvia ;
Bencheva, Leda Ivanova ;
Battisti, Umberto Maria ;
Tait, Annalisa ;
Sorbi, Claudia ;
Fossa, Paola ;
Cichero, Elena ;
Ronsisvalle, Simone ;
Arico, Giuseppina ;
Denora, Nunzio ;
Iacobazzi, Rosa Maria ;
Cilia, Antonio ;
Pirona, Lorenza ;
Brasili, Livio .
FUTURE MEDICINAL CHEMISTRY, 2018, 10 (18) :2137-2154
[48]   Dopamine D2L Receptor Deficiency Causes Stress Vulnerability through 5-HT1A Receptor Dysfunction in Serotonergic Neurons [J].
Shioda, Norifumi ;
Imai, Yoshiki ;
Yabuki, Yasushi ;
Sugimoto, Wataru ;
Yamaguchi, Kouya ;
Wang, Yanyan ;
Hikida, Takatoshi ;
Sasaoka, IbToshikuni ;
Mieda, EMic Hihiro ;
Fukunaga, Kohji .
JOURNAL OF NEUROSCIENCE, 2019, 39 (38) :7551-7563
[49]   Restraint accentuates the effects of 5-HT2 receptor antagonists and a 5-HT1A receptor agonist on lordosis behavior [J].
Uphouse, L ;
White, S ;
Harrison, L ;
Hiegel, C ;
Majumdar, D ;
Guptarak, J ;
Truitt, WA .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2003, 76 (01) :63-73
[50]   F15063, a potential antipsychotic with dopamine D2/D3 receptor antagonist, 5-HT1A receptor agonist and dopamine D4 receptor partial agonist properties: Influence on neuronal firing and neurotransmitter release [J].
Assie, Marie-Bernadette ;
Mnie-Filali, Ouissame ;
Ravailhe, Veronique ;
Benas, Christelle ;
Marien, Marc ;
Betry, Cecile ;
Zimmer, Luc ;
Haddjeri, Nasser ;
Newman-Tancredi, Adrian .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2009, 607 (1-3) :74-83